Karthik Viswanathan
Vice President, Research Visterra
Karthik joined Visterra in 2009 as its founding scientist and helped establish the Hierotope™ platform that has led to discovery and development of several therapeutics. He is an inventor of multiple drugs in different stages of clinical development including VIS649 (Sibeprenlimab) and VIS954. Karthik has authored over 40 publications in top-tiered journals including mAbs, Science, Cell, New England journal of Medicine and Nature Biotechnology in areas spanning protein engineering, therapeutic development, structural biology, glycobiology and infectious diseases. In addition, he is an inventor on over 50 patent and patent applications related to therapeutics products, technology platforms and vaccine design.
Prior to Visterra, Dr. Viswanathan was a postdoctoral researcher at Massachusetts Institute of Technology (MIT) where he worked on protein engineering technologies that eventually laid the foundation for Visterra. Karthik received his Bachelor of Technology in Biotechnology and Biochemical Engineering from the Indian Institute of Technology (IIT), Kharagpur, and a Ph.D. in Chemical and Biomolecular Engineering from Johns Hopkins University (JHU).
Seminars
- Discussing how emerging biology and novel mechanisms are expanding the therapeutic potential of complement beyond nephrology
- Exploring solutions to delivery, target engagement and sample collection challenges in difficult-to-access tissues
- Identifying the key factors for success in new indications, including target selection, patient stratification and translational validation
- Reviewing the latest clinical trial readouts, approvals and pipeline developments that are redefining the complement therapeutic landscape
- Distilling lessons from recent industry headlines, strategic collaborations and development challenges to guide future innovation and portfolio decisions
- Recapping recent development and strategizing the future of complement therapeutics
